Background/Aims: Vagus nerve stimulation (VNS) suppresses arrhythmic activity and minimizes cardiomyocyte injury. However, how VNS affects angiogenesis/arteriogenesis in infarcted hearts, is poorly understood. Methods: Myocardial infarction (MI) was achieved by ligation of the left anterior descending coronary artery (LAD) in rats. 7 days after LAD, stainlesssteel wires were looped around the left and right vagal nerve in the neck for vagus nerve stimulation (VNS). The vagal nerve was stimulated with regular pulses of 0.2ms duration at 20 Hz for 10 seconds every minute for 4 hours, and then ACh levels by ELISA in cardiac tissue and serum were evaluated for its release after VNS. Three and 14 days after VNS, Real-time PCR, immunostaining and western blot were respectively used to determine VEGF-A/B expressions and α-SMA-and CD31-postive vessels in VNS-hearts with pretreatment of α7-nAChR blocker mecamylamine (10 mg/kg, ip) or mACh-R blocker atropine (10 mg/kg, ip) for 1 hour. The coronary function and left ventricular performance were analyzed by Langendorff system and hemodynamic parameters in VNS-hearts with pretreatment of VEGF-A/B-knockdown or VEGFR blocker AMG706. Coronary arterial endothelial cells proliferation, migration and tube formation were evaluated for angiogenesis following the stimulation of VNS in coronary arterial smooth muscle cells (VSMCs). Results: VNS has been shown to stimulate VEGF-A and VEGF-B expressions in coronary arterial smooth muscle cells (VSMCs) and endothelial cells
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Introduction
Myocardial infarction (MI) damages cardiac function, leading to heart failure (HF) accompanied by an autonomic imbalance characterized by both increased sympathetic activity and decreased vagal activity [1] . Vagal nerve stimulation (VNS), a novel therapeutic strategy for autonomic dysfunction, has been shown to activate cholinergic anti-inflammatory pathways to improve cardiac function and long-term survival in MI patients and MI animal models besides its anti-adrenergic and anti-arrhythmic activities [2] [3] [4] [5] . However, whether or not VNS affects angiogenesis/arteriogenesis during the heart repair remains to be determined.
Angiogenesis (i.e. Growth of new blood vessels from preexisting ones) and arteriogenesis (i.e. the formation of collateral arteries from preexisting arterioles) are essential for reestablishing blood supply to the surviving myocardium and the recovery of ventricular function after MI [6] . The autonomic imbalance after MI impairs the angiogenesis in infarcted heart due to the decreased expressions of the α7-nicotinic acetylcholine (ACh) receptors (α7-nAChR) in MI-heart [7, 8] . Indeed, vagal innervation of the conduction system and coronary vessels in heart [9] and the increased ACh concentration in left ventricular and circulation are observed when exposed to VNS [2, [10] [11] [12] [13] . Since VNS mainly promotes α7-nAChR and m3-AChR expression in ischemia-reperfusion heart [14] , activation of either α7-nAChR or m3-AChR by ACh may mediate VNS-induced angiogenesis in infarcted heart. However, little is known about if and how VNS can promote angiogenesis and arteriogenesis.
Different member of the vascular endothelial growth factor (VEGF) family appears to have a specific function: VEGF-A induces angiogenesis in the heart, especially during hypoxia and nutrient deprivation [15, 16] . VEGF-B and VEGF-E mediates both angiogenesis and arteriogenesis [17, 18] , while VEGF-C and VEGF-D act mainly as lymphangiogenic factors [19] . Activation of α7-nAChR by nicotine has been shown to induce the expressions and releases of VEGF-A in endothelial cells (EC), triggering endothelial cell-mediated angiogenesis [7] . However, VEGF-A gene therapy does not lead to an increased angiogenesis or improved heart function [20] , indicating that other factors may also be required for VNS-induced angiogenesis. In the present study, we found that mainly VEGF-A and VEGF-B were induced in vascular smooth muscle cells (VSMCs) and ECs of coronary arteries along with increased angiogenesis and arteriogenesis after VNS. We thus hypothesized that VNS promoted angiogenesis and arteriogenesis in the injured heart through inducing both VEGF-A and VEGF-B.
Model establishment
MI was achieved by ligation of the left anterior descending coronary artery (LAD) as previously described [20] . Briefly, SD rats (250-300 g) were anesthetized with ketamine (50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Tracheal ventilation with room air was carried out by using a Colombus ventilator (HX-300, Taimeng Instruments, Chengdu, China). Following left lateral thoracotomy at the fourth intercostal space, the LAD was ligated. Before chest closure, infarction was confirmed by observation of the injury demarcation with blanching of the myocardium as well as electrocardiography.
Vagus nerve stimulation
A pair of Teflon-coated stainless-steel wires (UL1330; Triumph Cable Co, Ltd, Tonguing, China) was looped around the left and right vagal nerve in the neck for electrical stimulation. The wires were connected to the output terminals of the stimulator (BL-420S Data Acquisition & Analysis System; Chengdu Tme Technology Co, Ltd.), which provide stimulation over a range of frequencies (0.1-100 Hz), strengths (1-10 V) and pulse widths (0.001-10 sec). 7 days after the LAD ligation, survivors were randomized into groups with sham or active stimulation. In the actively stimulated group (VNS), the vagal nerve was stimulated with regular pulses of 0.2ms duration at 20 Hz for 10 seconds every minute for 4 hours [2, 5] . In the sham group (MI), similar procedures were executed without initiating the vagal nerve stimulation. The electrical voltage of pulses was optimized in each rat to obtain a 10% reduction in heart rate. To prevent drying and to provide insulation, the electrodes and the vagus nerve were immersed in a mixture of white petrolatum (Vaseline) and paraffin.
ELISA for ACh detection
To detect ACh levels in cardiac tissue and serum 4h after VNS, heart tissues and blood samples from six rats per group were collected and processed with cholinesterase inhibitor eserine (100 uM) added. ELISA for ACh was performed using a commercial kit by following the manufacture's protocol (ab65345, Abcam).
Ach receptor inhibitor treatment in vivo
The role of mACh-R and α7-nAChR in VNS-induced VEGF expressions in the infracted heart was assesses by administration of mecamylamine (10 mg/kg, ip) or atropine (10 mg/kg, ip) into six animals/ group 1 h before VNS, as described previously [14] . 
Knockdown of VEGF-A/B in vivo
To determine the effect of VEGF-A or VEGF-B on angiogenesis in the infracted heart, Ad-shCtrl, AdshVEGF-A, or Ad-shVEGF-B (1×10 9 pfu in 200 μl) were injected into four sites of the infarcted hearts (50 μl per site, 12 rats/group) with a 30-gauge tuberculin syringe 3 day before the VNS. Two injections were in the myocardium bordering the ischemic area and two within the ischemic area [20] . Penicillin (150, 000 U/mL, i.v.) was given before each procedure. Buprenorphine hydrochloride (0.05 mg/kg, s.c.) was administered twice a day for the first 48 hours after the procedure.
Measurement of hemodynamic parameters
Hemodynamic parameters were measured 28 days after each treatment as described previously [22] . Rats were anesthetized with ketamine (50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). The left carotid artery was isolated. A catheter filled with heparinized (10 U/mL) saline solution and connected to a Statham pressure transducer (Gould, Saddle Brook, NJ, USA) was inserted into the carotid artery and advanced into the left ventricle to record ventricular pressure. Hemodynamic parameters including left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and rate of rise and fall of ventricular pressure (+dP/dt max and -dP/dt max ) were measured simultaneously using BL-420s (Chengdu Tai-meng, Co, China). The heart was rapidly removed for other analyses after the measurements.
Coronary flow Assay
Six SD rats (250-300 g)/group were anesthetized with ketamine (50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). A thoracotomy was performed, and hearts rapidly excised into ice-cold perfusion fluid. The aorta was cannulated on a shortened and blunted 14-gauge needle, and perfusion initiated at a constant pressure of 80 mmHg on the Langendorff system. A fluid-filled balloon constructed from polyvinyl chloride film was introduced into the left ventricle through an incision in the left atrial appendage. Two tubes were introduced into the right atrial appendage through superior and inferior caval vein. Hearts were immersed in warmed perfusate in a jacketed bath maintained at 37°C, and perfusate delivered to the coronary circulation was maintained at the same temperature using a super constant temperature water bath. Organ bath and perfusate temperatures were continuously monitored using digital thermometer. Langendorff-perfused hearts were allowed to equilibrate until heart rate and contractility reached steady state for 30 min. Total coronary flow within 30 min was collected in the cylinder through tubes linked to right atrial appendage for evaluating coronary flow percentage/min. The Krebs-Henseleit perfusion fluid (containing NaCl, 119 mM; glucose, 11 mM; NaHCO 3 , 22 mM; KCl, 4.7 mM; MgCl 2 , 1.2 mM; KH 2 PO 4 , 1.2 mM; CaCl 2 , 2.5 mM; EDTA, 0.5 mM; and pyruvate, 2 mM) was used in all experiments. The fluid with a pH of 7.4 was bubbled with a mixture of 95% O 2 and 5% CO 2 at 37°C and was filtered through 0.45 μm filter before delivery to the heart [23] .
Cell cultures and groups
Human coronary microvessel endothelial cells (HCMECs), human vascular smooth muscle cells (HVSMCs) and human coronary artery endothelial cells (HCAECs) were purchased from the Jennio Biotech Co. Ltd (GuangZhou, China). To observe the effects of the different cells derived conditioned medium (CM) on HCAECs tube formation, CM from HVSMCs or HCAECs were generated as follows: for purpose of normalization, 3×10 6 HCAECs or HVSMCs were cultured in 100 mm 2 dish for 24 h in a complete medium. And then the cells were cultured for 24h in new complete medium with (CM-ACh) or without (CM-Ctrl) 10 To further addressed the possible signaling mechanism of the ACh-induced VEGF-A/B expressions in HVSMCs, mACh-R inhibitor atropine (1μM) or nACh-R inhibitor mecamylamine (7 μM), PI3K/Akt inhibitors Wortmannin (50 nM) and LY294002 (10 μM), eNOS inhibitor L-NAME (300 μM), MEK/ERK1/2 inhibitor PD98059 (50 μM), p38MAPK inhibitor SB203580 (30 μM) or Sp1 inhibitor mithramycin (1 μM, Sp1-I) were respectively pretreated for 1 hour, then treated with ACh (10 -5 M) for 24 hours. These cells were harvested and lysed in RAPI buffer with protease and phosphatase inhibitors for western blot.
EC tube formation assay
The corresponding CM were collected and centrifuged to remove the cells. EC tube formation was performed as described [24] . Briefly, HCAECs (4×10 5 /ml) were seeded in 96-well plates coated with Matrigel TM and incubated in the CM collected. Where indicated, 2 nM of AMG706 was added 30 minutes prior to changing to CM. For this assay, 3 duplicated wells/group were used, and the total number of tube branches (in pixels) per well was quantified using the Image-Pro Plus software package (Media Cybernetics, Carlsbad, CA) and averaged. The cells were then incubated at 37°C with 5% of CO 2 for 6 h, fixed in formalin, washed with PBS, imaged using microscopy. All measurements were repeated for 3 times and performed by two independent examiners who were blinded from the experimental groups.
For this assay, 3-4 wells/treated were performed, and the total number of tubes per well was quantified and averaged. Cells were incubated at 37°C for 16 h, fixed in formalin, washed with PBS, and imaged using microscopy. Number of tube branches (in pixels) was quantified using ImageJ software (NIH).
Cell Counting Kit-8
HVSMCs or HCAECs (2×10 4 cells/well) were seeded in 96-well plates and incubated for 24 h at 37°C followed by stimulation with growth factors. Thereafter, 10 μL of CCK-8 solution (Dojindo) was added to each well and incubated for 4. The samples were then detected at 450 nm by a microplate reader (Bio-Rad, Hercules, CA, USA), and analyzed using the mathematical formula [(OD value of test -OD value of blank)/ (OD value of control -OD value of blank)] to quantify the cell viability. In each group, three replicates were executed, and three or five independent experiments were implemented [25] .
Wound healing assay
HVSMCs or HCAECs were plated on a 6-well plate overnight with 10% FBS-containing DMEM and then starved for 12 h for synchronization. Each well was scratch-wounded with a micropipette tip and washed twice with PBS to remove the floating cells. The cells were then cultured in serum-free medium containing different dosage of VEGF-A or VEGF-B, and then digital images of the scratch-wound area were acquired at 0, 4, 8 h after wounding following dying with Crystal Violet Staining Solution. The gap areas relative to those measured at 0 h after wounding were quantified [25] .
Western blot
Western blot was carried out with rabbit polyclonal antibody against VEGF-B (1:1000; Abcam), Sp1, (1:1000; Santa Cruz), rabbit-anti-rat VEGF-A (1:1000; Abcam), p-Sp1 (1:1000; Abcam), Akt and pAkt (1:1000; Cell Signaling). Rat left ventricles were removed and grinded in liquid nitrogen. The samples were collected and homogenized on ice in a 0.1% Tween-20 homogenization buffer containing protease inhibitors. 50 µg of proteins were resolved in 10% SDS-PAGE gel and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore). After being blocked with 5% nonfat milk, the membrane was incubated with primary antibody (1:1000 dilution) for 90 min followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-rabbit IgG, anti-mouse IgG, 1:10000, Jackson ImmunoResearch). Protein expression was visualized by enhanced chemiluminescence reaction (Amersham Pharmacia Biotech) and quantified by densitometry [20] .
Immunostaining
Heart tissues were immersion-fixed in 4% paraformaldehyde and embedded in paraffin. Serial transverse sections (5 mm) were cut across the entire long axis of the heart and mounted on slides. After dewaxing, hydration and heat-induced antigen retrieval, heart specimens were incubated in a blocking buffer (PBS containing 5% goat serum and 0.1%Triton X-100) at room temperature for 1 h. Incubations in antibodies (diluted 1:250 in blocking buffer) were carried out at 4°C overnight for primary antibodies, [20, 26] .
Measurement of vascular density
The effect of VNS on vascular density was determined by quantifying the number of CD31 or ɑ-SMA positive vessels per squared millimeter in both the peri-infarction and infarction area in six animals each group. Measurements were performed on three equidistant sections between the apex and ligature (at the midpoint between the LAD ligature and the apex, between the midpoint and the LAD ligature, and between the midpoint and the apex). In each section, the number of CD31 or ɑ-SMA-positive vessels in eight equally distributed areas of 0.1 mm 2 in the infarction area and six equally distributed areas of 0.1 mm 2 in both peri-infarction areas were counted in blind fashion at a 20× magnification. The values were then expressed as the number of vessels per squared millimeter. All measurements were performed by two independent examiners who were blinded from the experimental groups using the Image-Pro Plus software package (Media Cybernetics, Carlsbad, CA) [27] .
Quantitative reverse transcription polymerase chain reaction (qPCR)
Total RNA from the tissues or cultured HVSMCs was extracted using TRIZOL Reagent (Roche). qPCR was performed using FastStart Universal SYBR Green Master (Roche). The primer sequences were listed in Table 1 . qPCR was performed on a Real-time PCR Detection System (ABI-7000).
Statistical analyses
Data shown are mean ± SD. Statistical significance between two groups was determined by paired or unpaired Student's t-test. Results for more than two experimental groups were evaluated by one-way ANOVA to specify differences between groups. P<0.05 was considered significant.
Results

Cardiac vagal innervation and ACh releases in infarcted hearts
The cardiac vagal innervation in the large and small coronary arteries was shown by double immunostaining of ɑ-SMA and VACHT (Fig. 1A) . Along with the VNS, there was an increase in ACh levels in heart tissues and serum (Fig.1B) , indicating that VNS caused cardiac vagus nerve to release more ACh.
VNS increased coronary blood flow
As the vagal neurotransmitter, ACh regulates coronary EC function and coronary blood flow [28, 29] . We used langendroff perfused heart system to evaluate coronary microvascular function ex vivo and found that VNS increased coronary blood flow of the infarcted hearts (Fig. 1C) , along with improved heart function ( Fig. 1D-1G ). However, these beneficial effects were abolished by either atropine (10 mg/kg, ip) or mecamylamine (10 mg/kg, ip) ( Fig. 1) , indicating 
that VNS improved coronary microvascular function through m-ACh-R and α7-nACh-R.
VNS induced angiogenesis and arteriogenesis through m/nACh-R
Recent studies showed that angiogenesis and arteriogenesis contribute to the improvement of coronary function [30] . In order to evaluate VNS effect on angiogenesis and arteriogenesis, CD31 (a mature endothelial cell marker) and α-SMA (a vascular smooth muscle cells marker) were used to quantify the number of capillary and artery vessels. As shown in Fig. 2A , the numbers of CD31-and α-SMApositive vessels were increased in VNS-treated hearts. The phenomena were abolished by either mACh-R inhibitor atropine (10 mg/kg, ip) or α7-nACh-R blocker mecamylamine (10 mg/kg, ip). Interestingly, mecamylamine showed a greater inhibition on VNS-induced formation of α-SMA-positive vessels VNS than atropine. These results together with the data shown in Fig. 1 supported the concept that both VNS-induced angiogenesis and arteriogenesis were critical for the improved coronary function.
VNS-induced VEGF expressions through m/n-ACh-R
Since VEGF family proteins play critical role in controlling angiogenesis [31] , we sought to determine if any member of the VEGF family is involved in VNSmediated angiogenesis. Thus, we examined the expression of VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E by real-time PCR and found that only VEGF-A and VEGF-B expression were markedly increased in the VNS-treated hearts (Fig. 3A) . Consistently, both VEGF receptors Flt1 and Flk1 were also increased in VNS-hearts as compared to the MI-hearts (Fig. 3B) . Immunostaining showed that VEGF-A and VEGF-B were induced mainly in ECs and VSMCs of small and large coronary vessels in infarction (Fig. 3C-3F ) and peri-infarction (Fig. 4A) areas of the infarcted hearts. 
Cellular Physiology and Biochemistry
Since VNS promoted m3-ACh-R and α7-nACh expression in the infarcted hearts ( Fig. 4C-4D ), we sought to determine if VNS-induced VEGF-A/B expression in coronary vessels was associated with m3-ACh-R and α7-nACh-R. Thus, atropine (10 mg/kg, ip) or mecamylamine (10 mg/kg, ip) were used to block Ach receptor activity 1 h before the VNS treatment. As shown in Fig. 4D , both atropine and mecamylamine abolished VNS-induced VEGF-A/B expression, suggesting that m3ACh-R and α7-nAChR activation was essential for VNSmediated VEGF-A/B expression.
VNS-induced VEGF was essential for the angiogenesis and arteriogenesis in infarcted hearts
To determine if VNS-induced VEGF-A/B play roles in angiogenesis and arteriogenesis, we knocked down either VEGF-A or VEGF-B using adenoviral delivery of their shRNA in Importantly, CD31-positive capillary density was lower in hearts with knockdown of VEGF-A than VEGF-B (Fig.  5A-5B) . Conversely, α-SMApositive arterial density was lower in hearts with knockdown of VEGF-B than VEGF-A (Fig. 5A-5C ). These effects were abrogated by VEGF receptor antagonist AMG 706 (Fig. 5A-5C ), further confirming that VNSinduced angiogenesis and arteriogenesis were regulated by VEGF-A and VEGF-B.
Functionally, adenoviral delivery of VEGF-A and VEGF-B shRNA or administration of AMG706 abolished the beneficial effects of VNS on coronary blood flows (Fig.  5D) , consisting with the changes in angiogenesis and arteriogenesis as shown in Fig. 5 . These data indicated that the improvement of VNSmediated coronary blood flow was attributable to VEGFs/VEGFR-induced angiogenesis and arteriogenesis.
VEGF-A was more potent than VEGF-B in inducing angiogenesis
VEGF promotes new capillary formation by inducing EC sprouting, proliferation and migration [17, 18] . To further determine if VNS-induced VEGF-A and VEGF-B were involved in angiogenesis of infarcted hearts, in vitro angiogenesis was assessed by measuring the capillary tube-like formation of human cardiac microvascular endothelial cells (HCMECs) and human coronary artery endothelial cells (HCAECs) on a nutrient-rich extracellular matrix gel. As shown in Fig. 6A , ACh-conditioned HCAEC culture medium ( HCAECs CM-GFP-ACh) promoted the formation of new tubes in vitro, which were associated with HCAECs, but not HCMECs. Knockdown of VEGF-A by shRNA or VEGFR blocker AMG706 abolished the effects of HCAECs CM-ACh on the tube formation (Fig. 6B-6C ). It appeared that knockdown of VEGF-B by shRNA only partially abrogated the HCAECs CM-GFP-ACh-caused tube formation (Fig. 6C ). In addition, VEGF-A markedly promoted HCAEC proliferation while both VEGFA and VEGF-B induced HCAECs migration (Fig. 6D and 6E) , indicating the synergetic action of VEGF-A and VEGF-B in angiogenesis. Similarly, ACh-conditioned VSMC culture medium ( HVSMCs CM-GFP-ACh) also promoted HCAEC tube formation, but this effect was abolished by AMG706 or knockdown of VEGF-A or VEGF-B (Fig. 6F-4G ). Interestingly, knockdown of VEGF-A almost completely abrogated the HVSMCs CM-GFP-ACh-induced tube formation (Fig.  6G) . These data indicated that VNS-induced angiogenesis was due to the activation of VEGFs/ 
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VEGFR signaling in coronary artery endothelial cells of infarcted hearts.
The synergetic effects of VEGF-A and VEGF-B on HVSMC proliferation and migration
Arteriogenesis is accompanied by differentiation, proliferation, and migration of VSMCs [30] . To test if VNSinduced VEGF-A and VEGF-B regulate VSMC phenotype in arteriogenesis of infarcted hearts, we used CCK-8 assay to analyze VSMC proliferation when exposed to different doses of VEGF-A or VEGF-B. We found that VEGF-A and VEGF-B dosage-dependently promoted VSMC proliferation (Fig. 6H) . VEGF-B appeared to have a greater effect in VSMC proliferation than VEGF-A. Moreover, wound healing assay showed that both VEGF-A and VEGF-B induced VSMC migration in dose-dependent manner (Fig. 6I) although VEGF-A exhibited a stronger effect on VSMC migration as compared with VEGF-B. Taken together, VEGF-B promoted VSMC proliferation while VEGF-A induced VSMC migration, indicating a cooperative function of VEGF-A and VEGF-B in the VNS-mediated arteriogenesis.
Sp1 transcription factor involved in VNS-induced VEGF-A/B expression
It is known that PI3K/ Akt, p38 MAPK, ERK1/2, and eNOS signaling regulate VEGF expression in ECs, endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) [24, 25, 28, 32] . To test if any of these signaling pathways is involved in VNS-induced VEGF-A/B expression, we used pathway-specific inhibitors to block the above-mentioned signal individually and observe if Ach-induced VEGF expression can be altered. We found that typical PI3K/Akt inhibitors both Wortmannin and LY294002 decreased the Ach-mediated VEGFA and VEGF-B expression (Fig. 7A-7B ), suggesting PI3K signaling regulated their expression. Indeed, Ach significantly increased the phosphorylated Akt level in ECs although the However, mAChR inhibitor atropine and α7-nAChR blocker mecamylamine abolished the activation of Akt (Fig. 7C-7D ). These data demonstrated that ACh induced VEGF expression through m/nAChR-PI3K/AKT signal pathway. Previous studies have shown that VEGF-A is regulated by transcription factor Sp1 [33] . To determine if AChinduced Akt phosphorylation causes Sp1 activation, and thus VEGF-A and VEGF-B gene transcription, total Sp1 (t-Sp1) and phosphorylated Sp1 (p-Sp1) were analyzed in HCAECs using western blot. As shown in Fig.  7C , ACh promoted the phosphorylation of transcription factor Sp1 (p-Sp1) while not affecting its expression (Fig. 7E) . However, atropine or mecamylamine almost completely blocked Ach-induced Sp1 phosphorylation. Importantly, Sp1 specific inhibitor mithramycin A abolished both VEGF-A and VEGF-B expression induced by ACh (Fig. 7F-7H ). These results indicated that ACh/m/nAChR/Akt/Sp1 signaling cascade mediated the VEGF-A/B gene transcription in response to ACh.
VNS improved cardiac structure and function
To determine if VNS-induced angiogenesis and arteriogenesis promote cardiac repair and improve heart function in infracted hearts, AMG706 were injected i.p. or adenovirus expressing VEGF-A or VEGF-B shRNA were injected in the infarcted hearts following VNS. Masson's trichrome staining showed severe heart fibrosis due to myocardium infarction. However, VNS significantly decreased the heart fibrosis ( Fig. 8A, 8C) . Moreover, VNS reduced the infarct size (Fig. 8B) , markedly increased LV wall thickness (Fig. 8D) . Consistent with the in vitro findings, the beneficial effect of VNS was abolished by AMG706, VEGF-A or VEGF-B shRNA.
Functional analysis showed that LV function including LVSP, LVEDP, +dP/dt max, and -dP/ dt max was significantly improved in VNS-treated hearts as compared to the MI animals ( Fig.  8E-8H ). AMG706 or VEGF shRNA, however, reduced VNS-improved LV function (Fig. 8E-8H ).
Discussion
Our studies made three novel observations. Firstly, we found that VNS-induced VEGF-A/B expression cooperatively regulated angiogenesis and arteriogenesis in infarcted heart. Secondly, VNS-triggered angiogenesis and arteriogenesis improved the coronary function Collateral artery growth or arteriogenesis is the primary approach for coronary arteries to maintain blood flow in the event of coronary arterial occlusions, being responsible for myocardium infarction [34] . An occluded artery is not normally replaced by one single large collateral vessel but rather by several smaller ones [30] . We found that VNS not only promoted angiogenesis characterized by the increased number of CD31 positive capillaries, but also induced the formation of α-SMA positive arteriogenesis in the MI-hearts. Functionally, VNS improved coronary blood flow (CBF) and heart function. These data suggested that synergistic effects of angiogenesis and arteriogenesis involved in VNS-mediated heart repair.
Publicated data have shown that VEGF family members play crucial roles in the formation of collateral arteries involving the proliferation and migration of VSMCs, adventitial fibroblasts in addition to ECs [30, 35] . VNS promoted VEGF-A and VEGF-B expression in coronary artery VSMCs and ECs of the infarcted hearts, resulting in the increased numbers of both CD31 positive capillaries and α-SMA positive arteries in vivo. Consistent with this observation, VEGF-A promoted HCAEC proliferation and HVSMC migration while VEGF-B induced HVSMC proliferation and HCAEC migration. Therefore, coordination of VEGF-A and VEGF-B appeared to better promote the repair of infarcted hearts through inducing both the angiogenesis and arteriogenesis after VNS.
Actually, coronary microvascular dysfunction, defined as impaired coronary flow reserve and/or coronary endothelial dysfunction, was associated with adverse cardiovascular events including death, nonfatal myocardial infarction, nonfatal stroke, and congestive heart failure [6] . Generally, the greater number of coronary arteries, the greater CBF [6, 28] . Our data documenting a relationship between CBF and VNS were consistent with other findings [28, 36] . Regarding as its short-term effects, VNS, as a novel therapy for autonomic dysfunction, could directly perform vascular protection and vasodilation to improve coronary microvascular function, resulting from released ACh [37] . Furthermore, similar to the response of coronary vasculature to intracoronary infusions of VEGF [38] , VNS could act as an adjuvant to increase CBF through activating VEGF, apart from released ACh. As for its long-term effects, expressions and releases of ACh-induced VEGF from both intima ECs and media VSMCs, as important providers of VEGF, maintained coronary endothelial cells function via stimulating angiogenesis in infracted hearts. Taken together, these data, along with previous findings that angiogenic factors induced coronary artery and microvessel formation in vivo [39, 40] , suggested that VNS could promote angiogenic factors-mediated angiogenesis and arteriogenesis to improve coronary function and left heart performance, which contributed to better explain the increased long-term survival rates of HF [41] .
Previous studied have shown that ACh protects cardiomyocytes through activating hypoxia-inducible factor 1α (HIF-1α) [10] . Although HIF-1α is a typical inducer for VEGF-A expression [42] , P13K/Akt signaling can increase VEGF-A expression via a HIF-1α-independent mechanism [43] . Our studies showed that ACh increased the Akt phosphorylation under normoxia condition, resulting in a higher phosphorylation of Sp1 and a greater expression of VEGF-A/B, comparable to p38MAPK-mediated Sp1 phosphorylation and VEGF-A expression [44] . Of interest, although Sp1 induced by ACh was important for the expression of both VEGF-A and VEGF-B, the Sp1-binding sequence is only present in the promoter region of VEGF-A, but not of VEGF-B. Therefore, other transcription factors are likely to be involved in Sp1-mediated VEGF-B expression, which may be investigated in the future.
The therapeutic expansion of blood vessel growth in patients suffering ischemic or infarcted diseases has become a challenge in clinical. In contrast to the promising results from animal studies and from a number of clinical phase I trials, several larger controlled studies testing VEGF-A, VEGF-C, VEGF-D, fibroblast growth factor 2 (FGF2), or FGF4 have shown that the gene therapy is safe despite the lack of clear benefit [45] [46] [47] [48] [49] . The main issues include: (1) the majority of experiments are performed with young healthy animals but target groups for arteriogenic therapy are elderly patients experiencing cardiovascular diseases; and (2) only one protein is applied for patients, which is probably the major problem in human acute [50, 51] . Previous studies showed that VEGF-A promoted angiogenesis in the ischemia heart [15, 16] , while VEGF-B acted as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation [52] . Our present studies have shown that the synergistic effect of VEGF-A and VEGF-B induced by VNS may better promote the angiogenesis and arteriogenesis in infarcted hearts, which provided a novel and valuable approach for gene therapy of cardiovascular diseases. Clinically, VNS have been widely recognized as typical cholinergic anti-inflammatory and anti-adrenergic activities. Herein, the beneficial effects of VNS on cardiac angiogenesis and arteriogenesis from coronary artery, cardiac function and remodeling of HF rats contributed to the synergistic effect of VEGF-A and VEGF-B. Although radio-controlled pulse generator to stimulate the vagal nerve was not used in the study [2, 44] , the method of VNS treatment used in the present study has been also frequently adopted in animal experimental [53, 54] . And the therapeutic modality used in the present study also brought a long-term favorable prognosis of HF through manipulating coronary artery. In a word, VNS should serve as a candidate choice of clinical treatment for MI and HF patients.
Taken together, our studies demonstrated that VNS improves coronary function and heart function through promoting angiogenesis and arteriogenesis in the infracted heart by activating both VEGF-A and VEGF-B signaling, which were regulated by the P13K/Akt-Sp1 signaling cascade.
Cellular Physiology and Biochemistry
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